Recognizing and managing the immunologic reactions in leprosy

Journal of the American Academy of Dermatology

Volumn 71, Issue 4, 2014, Pages 795-803

  Kamath, Sonia ^a   Vaccaro, Seth A ^a   Rea, Thomas H ^a   Ochoa, Maria T ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Erythema nodosum leprosum; Hansen disease; Leprosy; Lucio phenomenon; Reversal reaction; Type 1 reaction; Type 2 reaction.

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMYLOID A PROTEIN; AZATHIOPRINE; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; BETA DEFENSIN 3; C REACTIVE PROTEIN; CLOFAZIMINE; COMPLEMENT COMPONENT C1Q; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 6; METHOTREXATE; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; RIFAMPICIN; THALIDOMIDE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR; LEPROSTATIC AGENT;

ALBUMINURIA; ANALGESIA; ANEMIA; ANOREXIA; ANTIGEN ANTIBODY COMPLEX; ARTHRALGIA; ARTICLE; CELLULAR IMMUNITY; CLINICAL FEATURE; CONFUSION; DACTYLITIS; ERYTHEMA; ERYTHEMA NODOSUM LEPROSUM; FEVER; GLOMERULONEPHRITIS; HEPATOSPLENOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; IRITIS; LEUKOCYTOSIS; LUCIO PHENOMENON; LYMPHADENOPATHY; MALAISE; MYCOBACTERIUM LEPRAE; NECROTIZING ARTERITIS; NEUTROPHIL CHEMOTAXIS; ORCHITIS; PERIOSTITIS; PRIORITY JOURNAL; REVERSAL REACTION; SCHWANN CELL; SCREENING TEST; SKIN BIOPSY; SKIN DEFECT; SKIN EDEMA; DISABILITY; DISEASE COURSE; DRUG COMBINATION; ERYTHEMA NODOSUM; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LEPROMATOUS LEPROSY; LEPROSY; MALE; NECROSIS; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TYPE 1 REACTION; TYPE 2 REACTION; VASCULITIS;

ERYTHEMA NODOSUM LEPROSUM; HANSEN DISEASE; LEPROSY; LUCIO PHENOMENON; REVERSAL REACTION; TYPE 1 REACTION; TYPE 2 REACTION;

BIOPSY, NEEDLE; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ERYTHEMA NODOSUM; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; LEPROSTATIC AGENTS; LEPROSY; LEPROSY, LEPROMATOUS; MALE; NECROSIS; PREDNISONE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VASCULITIS;

EID: 84910146169     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.03.034     Document Type: Review

References (93)

1. World Health Organization. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser 2012;968:1-61.
2. Rodrigues LC, Lockwood DN. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011;11:464-70.
3. Walker SL, Lockwood DNJ. Leprosy type 1 (reversal) reactions and their management. Lepr Rev 2008;79:372-86.
4. Modlin RL, Rea TH. Leprosy: new insight into an ancient disease. J Am Acad Dermatol 1987;17:1-13.
5. Meyerson MS. Erythema nodosum leprosum. Int J Dermatol 1996;35:389-92.
6. Rea TH, Levan NE. Lucio's phenomenon and diffuse nonnodular lepromatous leprosy. Arch Dermatol 1978;114: 1023-8.
7. Sharma N, Koranne RV, Mendiratta V, Sharma RC. A study of leprosy reactions in a tertiary hospital in Delhi. J Dermatol 2004;31:898-903.
8. Manandhar R, LeMaster JW, Roche PW. Risk factors for erythema nodosum leprosum. Int J Lepro Other Mycobact Dis 1999;67:270-8.
9. Anderson H, Stryjewska B, Boyanton BL, Schwartz MR. Hansen disease in the United States in the 21st century. Arch Pathol Lab Med 2007;131:982-6.
10. National Hansen's Disease Program. A summary of Hansen's disease in the United States-2009. Baton Rouge: Department of Health and Human Services, Health Resources and Services Administration, National Hansen's Disease Program; 2011.
11. Truman RW, Singh P, Sharma R, Busso P, Rougemont J, Paniz-Mondolfi A, et al. Probable zoonotic leprosy in the Southern United States. N Engl J Med 2011;364:1626-33.
12. Kahawita IP, Walker SL, Lockwood DN. Leprosy type 1 reactions and erythema nodosum leprosum. An Bras Dermatol 2008;83:75-82.
13. Sehgal V. Reactions in leprosy: clinical aspects. Int J Dermatol 1987;26:278-86.
14. Goodless D, Ramos-Caro FA, Flowers F. Reactional states in Hansen's disease: practical aspects of emergency management. South Med J 1991;84:237-41.
15. Van Brakel WH, Nicholls PG, Das L, Barkataki P, Maddali P, Lockwood DN, et al. The INFIR cohort study: assessment of sensory and motor neuropathy in leprosy at baseline. Lepr Rev 2005;76:277-95.
16. Roche P, Theuvenet W, Britton W. Patients, risk factors for type 1 reactions in borderline leprosy. Lancet 1991;338:654-7.
17. Moschella SL. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol 2004;51:417-26.
18. Hogeweg M, Kiran KU, Suneetha S. The significance of facial patches and type I reaction for the development of facial nerve damage in leprosy: a retrospective study among 1226 paucibacillary leprosy patients. Lepr Rev 1991;62:143-9.
19. Shorey P, Krishnan MM, Dhawan S, Garg BR. Ocular changes in reactions in leprosy. Lepr Rev 1989;60:102-8.
20. Sehgal VN, Lamba PA. Ocular changes in leprosy. Int J Dermatol 1990;29:175-82.
21. Lockwood DN, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 1999;67:6-12.
22. Brandsma JW, Van Brakel WH. WHO disability grading: operational definitions. Lepr Rev 2003;74:366-73.
23. Trindade MAB, Benard G, Ura S, Ghidella CC, Avelleira JCR, Vianna FR, et al. Granulomatous reactivation during the course of a leprosy infection: reaction or relapse. PLoS Negl Trop Dis 2010;4:e921.
24. Narang T, Dogra S, Kaur I. Borderline tuberculoid leprosy with type 1 reaction in an HIV patientea phenomenon of immune reconstitution. Int J Lepr Other Mycobact Dis 2005;73:203-5.
25. Deps PD, Gripp CG, Madureira BP, Lucas EA. Immune reconstitution syndrome associated with leprosy: two cases. Int J STD AIDS 2008;19:135-6.
26. Menezes VM, Sales AM, Illarramendi X, Miranda A, Goncalves MM, Gutierrez-Galhardo MC. Leprosy reaction as a manifestation of immune reconstitution inflammatory syndrome: a case series of a Brazilian cohort. AIDS 2009;23:641-3.
27. Ustianowski A, Lockwood DN. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis 2006;6: 350-60.
28. Massone C, Talhari C, Ribeiro-Rodrigues R, Sindeaux RH, Mira MT, Talhari S, et al. Leprosy and HIV coinfection: a critical approach. Expert Rev Anti Infect Ther 2011;9:701-10.
29. Sarno EN, Illarramendi X, Nery JA, Gutierrez-Galhardo MC, Penna ML, Sampaio EP, et al. HIV-M leprae interaction: can HAART modify the course of leprosy? Public Health Rep 2008; 123:206-12.
30. Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis 2006;43:e19-22.
31. Camacho ID, Valencia I, Rivas MP, Burdick AE. Type 1 leprosy reaction manifesting after discontinuation of adalimumab therapy. Arch Dermatol 2009;145:349-51.
32. Scharschmidt TC, Amerson EH, Rosenberg OS, Jacobs RA, McCalmont TH, Shinkai K. Immune reconstitution reactions in human immunodeficiency virusenegative patients. JAMA Dermatol 2013;149:74-8.
33. Richardus JH, Nicholls PG, Croft RP, Withington SG, Smith WCS. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. Int J Epidemiol 2004;33:337-43.
34. Walker SL, Nicholls PG, Butlin CR, Nery JAC, Roy HK, Rangel E, et al. Development and validation of a severity scale for leprosy type 1 reactions. PLoS Negl Trop Dis 2008;2:e351.
35. Anderson AM, Croft RP. Reliability of Semmes Weinstein monofilament and ballpoint sensory testing, and voluntary muscle testing in Bangladesh. Lepr Rev 1999;70:305-13.
36. Suresh M, Nicholls PG, Das L, Van Brakel WH. Voluntary muscle testing and dynamometry in diagnosis of motor impairment in leprosy: a comparative study within the INFIR cohort study. Lepr Rev 2008;79:277-94.
37. Lockwood DNJ, Lucas SB, Desikan KV, Ebenezer G, Suneetha S, Nicholls P. The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol 2008;61:595-600.
38. Lockwood DNJ, Nicholls P, Smith WC, Das L, Barkataki P, Van Brakel W, et al. Comparing the clinical and histological diagnosis of leprosy and leprosy reactions in the INFIR cohort of Indian patients with multibacillary leprosy. PLoS Negl Trop Dis 2012;6:e1702.
39. Sehgal VN, Srivastava G, Sundharam JA. Immunology of reactions in leprosy. Int J Dermatol 1988;27:157-62.
40. Wang XH, Ohmen JD, Uyemura K, Rea TH, Kronenberg M, Modlin RL. Selection of T lymphocytes bearing limited T-cell receptor beta chains in the response to a human pathogen. Proc Natl Acad Sci U S A 1993;90:188-92.
41. Lockwood DNJ, Colston MJ, Khanolkar-Young SR. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg 2002;66:409-15.
42. Narayanan RB, Laal S, Sharma K, Bhutani LK, Nath I. Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Clin Exp Immunol 1984;55:623-8.
43. Little D, Khanolkar-young S, Coulthart A, Suneetha S, Lockwood DNJ. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 2001;69:3413-7.
44. Lockwood DNJ, Suneetha L, Sagili KD, Chaduvula MV, Mohammed I, Van Brakel W, et al. Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort. PLoS Negl Trop Dis 2011;5:e1327.
45. Scollard DM, Chaduvula MV, Martinez A, Fowlkes N, Nath I, Stryjewska BM, et al. Increased CXC ligand 10 levels and gene expression in type 1 leprosy reactions. Clin Vaccine Immunol 2011;18:947-53.
46. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumor necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 1991;84:103-8.
47. Oliveira RB, Ochoa MT, Sieling PA, Rea TH, Rambukkana A, Sarno EN, et al. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun 2003;71:1427-33.
48. Misch EA, Macdonald M, Ranjit C, Sapkota BR, Wells RD, Siddiqui MR, et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl Trop Dis 2008;2: e231.
49. Cogen AL, Walker SL, Roberts CH, Hagge DA, Neupane KD, Khadge S, et al. Human beta-defensin 3 is up-regulated in cutaneous leprosy type 1 reactions. PLoS Negl Trop Dis 2012; 6:e1869.
50. Saunderson P, Gebre S, Desta K. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors, and outcome. Lepr Rev 2000;71:285-308.
51. Croft RP, Nicholls P, Richardus JH, Smith WC. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev 2000;71: 154-68.
52. Legendre DP, Muzny CA, Swiatlo E. Hansen's disease (leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. Pharmacotherapy 2012;32:27-37.
53. Health Resources and Services Administration. Managing reactions. Available from: URL:http://www. hrsa. gov/hansens disease/diagnosis/reactions. html. Accessed November 29, 2013.
54. Papang R, John AS, Abraham S, Rao PS. A study of steroid-induced diabetes mellitus in leprosy. Indian J Lepr 2009;81:125-9.
55. Schram ME, Borgonjen RJ, Bik CM, Van der Schroeff JG, Van Everdingen JJE, Spuls PI, et al. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol 2011;147:474-88.
56. Marlowe SNS, Hawksworth RA, Butlin R, Nicholls PG, Lockwood DN. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg 2004;98:602-9.
57. Marlowe SN, Leekassa R, Bizuneh E, Knuutilla J, Ale P, Bhattarai B, et al. Response to cyclosporin treatment in Ethiopian and Nepali patients with severe leprosy type 1 reactions. Trans R Soc Trop Med Hyg 2007;101:1004-12.
58. Biosca G, Casallo S, Lopez-Velez R. Methotrexate treatment for type 1 (reversal) leprosy reactions. Clin Infect Dis 2007;45: e7-9.
59. Safa G, Darrieux L, Coic A, Tisseau L. Type 1 leprosy reversal reaction treated with topical tacrolimus along with systemic corticosteroids. Indian J Med Sci 2009;63:359-62.
60. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175:1729-37.
61. Rea TH, Levan NE. Erythema nodosum leprosum in a general hospital. Arch Dermatol 1975;111:1575-80.
62. Chakma JK, Malaviya GN, Girdhar A, Hussein S. Florid reactive periostitis ossificans of long bones and digits associated with reaction in a patient with leprosy. Lepr Rev 2012;83:98-103.
63. Kahawita IP, Lockwood DNJ. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008;102:329-37.
64. Sehgal VN, Bhattacharya SN, Shah Y, Sharma VK, Gupta CK. Reaction in leprosy: acute phase reactant response during and after remission. Int J Dermatol 1992;31:632-4.
65. Chopra R, Chhabra S, Thami GP, Punia RS. Panniculitis: clinical overlap and the significance of biopsy findings. J Cutan Pathol 2010;37:49-58.
66. Lee DJ, Li H, Ochoa MT, Tanaka M, Carbone RJ, Damoiseaux R, et al. Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Invest Dermatol 2010;201:558-61.
67. Modlin RL, Gebhard JF, Taylor CR, Rea TH. In situ characterization of T-lymphocyte subsets in the reactional states of leprosy. Clin Exp Immunol 1983;53:17-24.
68. Sreenivasan P, Misra R, Wilfred D, Nath I. Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions. Immunology 1998;95:529-36.
69. Goulart IMB, Mineo JR, Foss NT. Production of transforming growth factor-beta-1 by blood monocytes from patients with different clinical forms of leprosy. Clin Exp Immunol 2000; 122:330-4.
70. Sousa ALM, Fava VM, Sampaio LH, Martelli CMT, Costa MB, Mira MT, et al. Genetic and immunological evidence implicates interleukin 6 as a susceptibility gene for leprosy type 2 reaction. J Infect Dis 2012;205:1417-24.
71. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
72. Haslett PA, Roche P, Butlin CR, Macdonald M, Shrestha N, Manandhar R, et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis 2005;192:2045-53.
73. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S. T. E. P. S. TM: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319-30.
74. Walker S, Waters M, Lockwood D. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007;78:197-215.
75. Fabi SG, Hill C, Witherspoon JN, Boone SL, West DP. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. J Drugs Dermatol 2009;8:765-9.
76. Yamaguchi S, Yamamoto Y, Hosokawa A, Hagiwara K, Uezato H, Takahashi K. Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy. J Dermatol 2012;39:711-4.
77. Vetrichevvel TP, Pise GA, Thappa DM. A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. Lepr Rev 2008;79:193-5.
78. Van Brakel W, Cross H, Declercq E, Deepak S, Lockwood D, Saunderson P, et al. Review of leprosy research evidence (2002-2009) and implications for current policy and practice. Lepr Rev 2010;81:228-75.
79. Van Veen N, Lockwood D, Van Brakel W, Ramirez J, Richardus JH. Interventions for erythema nodosum leprosum: a Cochrane review. Lepr Rev 2009;80:355-72.
80. Sales AM, De Matos HJ, Nery JAC, Duppre NC, Sampaio EP, Sarno EN. Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. Braz J Med Biol Res 2007;40:243-8.
81. Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis 2011;52: e133-5.
82. Hossain D. Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients. Lepr Rev 2013;84:105-12.
83. Lydakis C, Ioannidou D, Koumpa I, Giannikaki E, Thalassinos E, Krasoudaki E, et al. Development of lepromatous leprosy following etanercept treatment for arthritis. Clin Rheumatol 2012;31:395-8.
84. Sehgal VN. Lucio's phenomenon/erythema necroticans. Int J Dermatol 2005;44:602-5.
85. Han XY, Jessurun J. Severe leprosy reactions due to Mycobacterium lepromatosis. Am J Med Sci 2013;345:65-9.
86. Roverano S, Paira S, Somma F. Lucio's phenomenon: report of two cases and review of the literature. J Clin Rheumatol 2000;6:210-3.
87. Pursley TV, Jacobson RR, Apisarnthanarax P. Lucio's phenomenon. Arch Dermatol 1980;116:201-4.
88. Rea TH, Jerskey RS. Clinical and histologic variations among thirty patients with Lucio's phenomenon and pure and primitive diffuse lepromatosis (Latapi's lepromatosis). Int J Lepr Other Mycobact Dis 2005;73:169-88.
89. Ang P, Tay YK, Ng SK, Seow C. Fatal Lucio's phenomenon in 2 patients with previously undiagnosed leprosy. J Am Acad Dermatol 2003;48:958-61.
90. Rea TH, Ridley DS. Lucio's phenomenon: a comparative histological study. Int J Lepr Other Mycobact Dis 1979;47: 161-6.
91. Magana M, Fernandez-Diez J, Magana ML. Lucio's phenomenon is a necrotizing panvasculitis: mostly a medium-sized granulomatous arteritis. Am J Dermatopathol 2008;30:555-60.
92. Han XY, Seo YH, Sizer KC, Schoberle T, May GS, Spencer JS, et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 2008;130:856-64.
93. Piepkorn M, Brown C, Zone J. Auricular chondritis as a rheumatologic manifestation of Lucio's phenomenon: clinical improvement after plasmapheresis. Ann Intern Med 1983;98: 49-51.